1. Scrip
  3. >>Financing

Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs

Harbour BioMed And Jacobio Went Public In Hong Kong

 
• By Mandy Jackson

Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.

Finance Watch

BioAtla, Inc., Virios Therapeutics, Inc. and Scopus BioPharma Inc. brought the number of initial public offerings by biopharmaceutical companies in the US to 85 so far in 2020 as investors prepared to take a break from IPO at the end of the year.

The BioAtla, Virios and Scopus priced offerings follow IPOs by AbCellera Biologics Inc., 4D Molecular Therapeutics LLC and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?